Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | MC3R | P41968 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2848952 | 0.80 | LMNA (0.59) | KDM4ENAPRTALDH1A1MAPTGAA | |
| SCHEMBL12043756 | 0.80 | ALDH1A1 (0.47) | KDM4ENAPRTHCAR2TSHRADORA3 | |
| SCHEMBL2192774 | 0.76 | PTGIR (0.51) | KDM4ENAPRTHCAR2TSHRALDH1A1 | |
| SCHEMBL29058740 | 0.76 | SIRT6 (0.46) | NAPRTTSHRADORA3MC4RADRA1A | |
| SCHEMBL13817566 | 0.74 | HTT (0.65) | HCAR2TSHRALDH1A1ALOX15MAPT | |
| SCHEMBL16011500 | 0.74 | KDM4E (0.59) | KDM4ENAPRTHCAR2TSHRADORA3 | |
| SCHEMBL30593013 | 0.73 | KMT2A (0.63) | KDM4ENAPRTHCAR2TSHRADORA3 | |
| Biphenyl SCHEMBL10419668 | 0.73 | NAPRT (0.77) | KDM4ENAPRTHCAR2TSHRADORA3 | |
| SCHEMBL28269739 | 0.73 | KDM4E (0.53) | KDM4ENAPRTHCAR2TSHRADORA3 | |
| SCHEMBL4019791 | 0.73 | KMT2A (0.63) | KDM4ENAPRTHCAR2TSHRADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812418-B1 | DIBENZOSUBERONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-10-27 | — | — | EP | disclosed |
| EP-1716132-B1 | SPIRO-BENZODIOXOLES AND THEIR USE AS CB1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-08-25 | — | — | EP | disclosed |
| CN-101052632-A | Dibenzosuberone derivatives | HOFFMANN LA ROCHE (CH) | 2007-10-10 | — | — | CN | disclosed |
| EP-1812418-A1 | DIBENZOSUBERONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| US-7220743-B2 | Heterocyclic CB1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7144890-B2 | Spiro-pentacyclic compounds | HOFFMAN-LA ROCHE INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1716132-A2 | SPIRO-BENZODIOXOLES AND THEIR USE AS CB1 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| WO-2006050842-A1 | DIBENZOSUBERONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | disclosed |
| US-20060100206-A1 | Heterocyclic CB1 receptor antagonists | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-05-11 | — | — | US | disclosed |
| WO-2005075450-A2 | SPIRO-BENZODIOXOLES AND THEIR USE AS CB1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-18 | — | — | WO | disclosed |
| US-20050165012-A1 | Spiro-pentacyclic compounds | HOFFMANN-LA ROCHE INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100206-A1 | Heterocyclic CB1 receptor antagonists | CNR1, CNR2, HCRTR2 | KDM4E 2067/4885NAPRT 847/4885HCAR2 20/4885 |
| US-20050165012-A1 | Spiro-pentacyclic compounds | CNR1, CNR2, GPR119 | KDM4E 3522/4885NAPRT 612/4885HCAR2 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.